A new industry report shows the global research peptide market has reached $1.9 billion in 2026, driven by therapeutic demand and projected to hit $2.59 billion by 2031.
BioLongevity Labs has published its 2026 Research Peptide Vendor Report, documenting that the global peptide synthesis market has reached approximately $1.9 billion this year. The report projects continued growth at a 6.39 percent compound annual rate, with the market on track to reach $2.59 billion by 2031.
The surge is being driven by multiple factors: expanding clinical applications for GLP-1 agonists in obesity and diabetes, renewed regulatory access to compounded peptides following the February 2026 reclassification, and growing interest from the longevity and performance optimization communities. The report also highlights rising quality standards across the industry, with third-party testing and certificate-of-analysis documentation becoming baseline expectations rather than premium differentiators.
Notably, the vendor landscape has consolidated significantly over the past year. Stricter enforcement against unlicensed sellers and the return of compounding pharmacy access have shifted demand toward regulated channels, benefiting established manufacturers while squeezing out gray-market suppliers.
Source: GlobeNewsWire
Share this article
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.